# Study of CS-3150 in Patients With Essential Hypertension

Study · id `cardio:ct-nct02890173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02890173](<https://clinicaltrials.gov/study/NCT02890173>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02890173

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1001 participants.

## Technical summary

Registry record NCT02890173. Randomized; quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-07-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1001 participants (enrolled count; ClinicalTrials.gov record NCT02890173, source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)
- Start date: 2016-09 (registry gives no type) (ClinicalTrials.gov record NCT02890173, source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)
- Primary completion: 2017-07-11 (actual) (ClinicalTrials.gov record NCT02890173, source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)
- Completion: 2017-07-11 (actual) (ClinicalTrials.gov record NCT02890173, source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02890173, source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02890173-2018-12-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of CS-3150 in Patients With Essential Hypertension
- Acronym: ESAX-HTN
- Condition: Essential Hypertension
- Intervention (Drug): CS-3150
- Intervention (Drug): Eplerenone
- Lead sponsor: Daiichi Sankyo Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo Co., Ltd. (`cardio:org-daiichi-sankyo-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study) (`cardio:pubmed-31786983`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a6b537bd556b4b6f3f88445f5b875ab5cb60986f854b96423a6c65a97183d5b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
